The partnership’s objective is twofold: to empower Novartis’ drug discovery and development team with the help of advanced AI software, and to use AI to explore and speed the development of potential new gene and cell therapies. Microsoft’s AI will be applied to every stage of the development process, including research, clinical trials and manufacturing.
“As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend patients’ lives,” Novartis CEO Vas Narasimhan, MD, said. “Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world.”
More articles on AI:
Penn Medicine predictive system increases palliative care consults by 74%
AHA: 6 crucial components for integrating AI into healthcare workforce
Mayo Clinic joins $20M funding for startup fighting heart disease with AI
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
